A review of AbobotulinumtoxinA (Dysport)

Aesthet Surg J. 2013 Mar;33(1 Suppl):13S-7S. doi: 10.1177/1090820X12474632.

Abstract

AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Face
  • Humans
  • Neurotransmitter Agents / adverse effects
  • Neurotransmitter Agents / therapeutic use*
  • Rejuvenation*
  • Treatment Outcome

Substances

  • Neurotransmitter Agents
  • Botulinum Toxins, Type A
  • abobotulinumtoxinA